Your browser doesn't support javascript.
loading
An Exploratory Study of Sleep-Wake Differences of Autonomic Activity in Patients with Mild Cognitive Impairment: The Role of Melatonin as a Modulating Factor.
Abulafia, Carolina; Vidal, María F; Olivar, Natividad; Odzak, Andrea; Brusco, Ignacio; Guinjoan, Salvador M; Cardinali, Daniel P; Vigo, Daniel E.
Afiliação
  • Abulafia C; Laboratory of Chronophysiology, Institute for Biomedical Research (BIOMED), Pontifical Catholic University of Argentina (UCA) and CONICET, Buenos Aires, Argentina.
  • Vidal MF; Facultad de Psicología, Universidad de Buenos Aires, Buenos Aires, Argentina.
  • Olivar N; Servicio de Psiquiatría, Departamento de Neurología, Fleni, Buenos Aires, Argentina.
  • Odzak A; Hospital de Clínicas "José de San Martín", Universidad de Buenos Aires, Buenos Aires, Argentina.
  • Brusco I; Servicio de Clínica Médica, Hospital Argerich, Buenos Aires, Argentina.
  • Guinjoan SM; Hospital de Clínicas "José de San Martín", Universidad de Buenos Aires, Buenos Aires, Argentina.
  • Cardinali DP; Servicio de Clínica Médica, Hospital Argerich, Buenos Aires, Argentina.
  • Vigo DE; CONICET, Buenos Aires, Argentina.
Clin Interv Aging ; 18: 771-781, 2023.
Article em En | MEDLINE | ID: mdl-37200894
Purpose: The objective of the present study was to assess sleep-wake differences of autonomic activity in patients with mild cognitive impairment (MCI) compared to control subjects. As a post-hoc objective, we sought to evaluate the mediating effect of melatonin on this association. Patients and Methods: A total of 22 MCI patients (13 under melatonin treatment) and 12 control subjects were included in this study. Sleep-wake periods were identified by actigraphy and 24hr-heart rate variability measures were obtained to study sleep-wake autonomic activity. Results: MCI patients did not show any significant differences in sleep-wake autonomic activity when compared to control subjects. Post-hoc analyses revealed that MCI patients not taking melatonin displayed lower parasympathetic sleep-wake amplitude than controls not taking melatonin (RMSSD -7 ± 1 vs 4 ± 4, p = 0.004). In addition, we observed that melatonin treatment was associated with greater parasympathetic activity during sleep (VLF 15.5 ± 0.1 vs 15.1 ± 0.1, p = 0.010) and in sleep-wake differences in MCI patients (VLF 0.5 ± 0.1 vs 0.2 ± 0.0, p = 0.004). Conclusion: These preliminary findings hint at a possible sleep-related parasympathetic vulnerability in patients at prodromal stages of dementia as well as a potential protective effect of exogenous melatonin in this population.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos do Sono-Vigília / Disfunção Cognitiva / Melatonina Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos do Sono-Vigília / Disfunção Cognitiva / Melatonina Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article